Harrow Health, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on December 13, 2022, by Harrow Health, Inc. (formerly Harrow, Inc.), a Delaware corporation. The filing discloses the entry into a Material Definitive Agreement regarding the acquisition of ophthalmic product assets.
Key Financial Metrics and Transaction Terms
The filing details a significant asset acquisition rather than standard periodic financial results. Key financial terms include:
- Upfront Payment: $130,000,000 payable at closing.
- Milestone Payment: Up to $45,000,000 contingent on the commercial availability of Triesence.
- Total Potential Consideration: Up to $175,000,000.
- Revenue/Profit/Liquidity: The filing text does not provide current revenue, profit, cash flow, or liquidity metrics for the reporting period.
Material Changes and Acquisition Details
On December 13, 2022, the Company entered into an Asset Purchase Agreement with Novartis Technology, LLC and Novartis Innovative Therapies AG to acquire exclusive U.S. commercial rights to the following ophthalmic products:
- ILEVRO (nepafenac ophthalmic suspension) 0.3%
- NEVANAC (nepafenac ophthalmic suspension) 0.1%
- VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%
- MAXIDEX (dexamethasone ophthalmic suspension) 0.1%
- TRIESENCE (triamcinolone acetonide injectable suspension) 40 mg/ml
The acquisition is expected to close in the first quarter of 2023, subject to customary conditions including Hart-Scott Rodino Antitrust Improvements Act clearance.
Outlook, Management Commentary, and Risks
Transition Period: Following closing, Novartis will continue to sell the products on the Company's behalf for approximately six months prior to the transfer of New Drug Applications (NDAs). During this period, Novartis will transfer net profits from sales to the Company.
Supply and Manufacturing: Novartis has agreed to supply certain products post-transfer and assist with technology transfer to third-party manufacturers if needed.
Risks: The transaction is subject to regulatory clearance and customary closing conditions. The filing does not provide specific guidance on future financial performance beyond the transaction terms.
Investor Verification Checklist
- Verify the Company's current cash position and debt capacity to fund the $130 million upfront payment.
- Monitor the status of Hart-Scott Rodino Antitrust Improvements Act clearance for the Q1 2023 closing target.
- Review the specific terms of the net profit transfer mechanism during the six-month transition period.
- Assess the commercial viability and market competition for the acquired ophthalmic portfolio (ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, TRISENCE).